دورية أكاديمية
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study
| العنوان: | Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study |
|---|---|
| المؤلفون: | Macaluso, Fabio Salvatore, Principi, Mariabeatrice, Facciotti, Federica, Contaldo, Antonella, Todeschini, Alessia, Saibeni, Simone, Bezzio, Cristina, Castiglione, Fabiana, Nardone, Olga Maria, Spagnuolo, Rocco, Fantini, Massimo Claudio, Riguccio, Gaia, Caprioli, Flavio, Viganò, Chiara, Felice, Carla, Fiorino, Gionata, Correale, Carmen, Bodini, Giorgia, Milla, Monica, Scardino, Giulia, Vernero, Marta, Desideri, Federico, Mannino, Mariella, Rizzo, Giuseppe, Orlando, Ambrogio |
| المساهمون: | Macaluso, Fabio Salvatore, Principi, Mariabeatrice, Facciotti, Federica, Contaldo, Antonella, Todeschini, Alessia, Saibeni, Simone, Bezzio, Cristina, Castiglione, Fabiana, Nardone, Olga Maria, Spagnuolo, Rocco, Fantini, Massimo Claudio, Riguccio, Gaia, Caprioli, Flavio, Viganò, Chiara, Felice, Carla, Fiorino, Gionata, Correale, Carmen, Bodini, Giorgia, Milla, Monica, Scardino, Giulia, Vernero, Marta, Desideri, Federico, Mannino, Mariella, Rizzo, Giuseppe, Orlando, Ambrogio |
| بيانات النشر: | ELSEVIER SCIENCE INC |
| سنة النشر: | 2023 |
| المجموعة: | Padua Research Archive (IRIS - Università degli Studi di Padova) |
| مصطلحات موضوعية: | Biologic, SARS-CoV-2, Vaccines |
| الوصف: | Background: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. Aims: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel dis-ease (IBD) Methods: E ffectiveness and S af ety of C OVID-19 V a ccine in P ati e nts with Inflammatory B owel D isease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs).Results: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p < 0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole co-hort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p < 0.001) and the subgroup of IBD patients (n = 280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0-4.1]; p < 0.001). Conclusions: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magni-tude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTri-als.govID:NCT04769258).(c) 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36127228; info:eu-repo/semantics/altIdentifier/wos/WOS:000927018700001; volume:55; issue:2; firstpage:154; lastpage:159; numberofpages:6; journal:DIGESTIVE AND LIVER DISEASE; https://hdl.handle.net/11577/3474429Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85138024171 |
| DOI: | 10.1016/j.dld.2022.08.027 |
| الإتاحة: | https://doi.org/10.1016/j.dld.2022.08.027Test https://hdl.handle.net/11577/3474429Test |
| رقم الانضمام: | edsbas.E923C214 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.dld.2022.08.027 |
|---|